Polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients

Pakistan Journal of Medical Sciences

Volumn 30, Issue 5, 2014, Pages

  Dong Ju, Zhao ^a   Ai Ju, Xiao ^a   Yun Jiao, Tian ^a   Ming Qiu, Zhang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Clinical outcome; Osteosarcoma; Vascular endothelial growth factors

Indexed keywords

ADENINE; CYTOSINE; GUANINE; THYMINE;

ADULT; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; VEGF GENE; WILD TYPE;

EID: 84905096281     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.305.5170     Document Type: Article

References (24)

1. Duong LA, Richardson LC. Descriptive Epidemiology of Malignant Primary Osteosarcoma Using Population-based Registries, United States, 1999-2008. J Registry Manag. 2013;40(2):59-64.
2. Savage SA, Woodson K, Walk E, Modi W, Liao J, Douglass C, et al. Analysis of genes critical for growth regulation identifies Insulin-like Growth Factor 2 Receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1667-1674. doi: 10.1158/1055-9965.EPI-07-0214.
3. Ries LAG, SEER Program (National Cancer Institute (U.S.). Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995/ed. by Lynn A. Gloecker Ries et al. National Cancer Institute, SEER Program, Bethesda, MD, USA, 1999.
4. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32(6):423-436. doi:10.1016/j. ctrv.2006.05.005.
5. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3-13. doi: 10.1007/978-1-4419-0284-9_1.
6. Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65:1123-1132.
7. Kager L, Zoubek A, Potschger U. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011-2018. doi: 10.1200/ JCO.2003.08.132
8. Yang LM, Li XH, Bao CF. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors. Asian Pac J Cancer Prev. 2012;13(11):5883-5886. doi: 10.7314/APJCP.2012.13.11.5883.
9. Bai SB, Chen HX, Bao YX, Luo X, Zhong JJ. Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma. Asian Pac J Cancer Prev. 2013;14(6):3677-3680. doi: 10.7314/APJCP.2013.14.6.3677
10. Teng JW, Yang ZM, Li J, Xu B. Predictive role of Glutathione S-transferases (GSTs) on the prognosis of osteosarcoma patients treated with chemotherapy. Pak J Med Sci. 2013;29(5):1182-1186. doi: 10.12669/pjms.295.3870
11. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996;93(8):1493-1495. doi: 10.1161/01.CIR.93.8.1493
12. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232-1235. doi: 10.1006/cyto.2000.0692
13. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004;46(3):293-298. doi: 10.1016/j. lungcan.2004.04.037
14. Yu XW, Wu TY, Yi X, Ren WP, Zhou ZB, Sun YQ, et al. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol. 2014;35(1):155-160.
15. Chen D, Zhang YJ, Zhu KW, Wang WC. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol. 2013;34(3):1895-1899. doi: 10.1007/s13277-013-0733-z.
16. Rastogi S, Kumar R, Sankineani SR, Marimuthu K, Rijal L, Prakash S, et al. Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study. Int Orthop. 2012;36(11):2315-2321. doi: 10.1007/s00264-012-1663-x.
17. Wang Z, Wen P, Luo X, Fang X, Wang Q, Ma F, Lv J. Association of the vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population. Tumour Biol. 2014;35(4):3605-3610. doi: 10.1007/s13277-013-1475-7.
18. Salven P, Teerenhovi L, Joensuu H. A high pre-treatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 1997;90:3167-3172.
19. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37(6):443-448. doi: 10.1159/000054076
20. Lee SJ, Lee SY, Jeon HS, Park SH, Jang JS, Lee GY, et al. Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol, Biomarkers Prev. 2005;14(3):571-575. doi: 10.1158/1055-9965.EPI-04-0472
21. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004;46(3):293-298. doi: 10.1016/j. lungcan.2004.04.037.
22. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009;8(9):2496-2508. doi: 10.1158/1535-7163.MCT-09-0302.
23. Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, et al. VEGF-A polymorphisms predict progression-free survival among advanced castrationresistant prostate cancer patients treated with metronomic cyclophosphamide. Br J Cancer. 2013;109(4):957-964. doi: 10.1038/bjc.2013.398.
24. Tamura T, Kuwahara A, Yamamori M, Nishiguchi K, Nakamura T, Okuno T, et al. VEGF-634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci. 2012;9(10):833-837. doi: 10.7150/ijms.4914.